Business
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
LEXINGTON, Mass., March 19, 2025--Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care.
About this update from Agenus Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Patients and Healthcare Providers Alike Call for More Innovative, Less Toxic Treatment Options","length":94,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CRC Diagnoses Rise While Current Standards Fall Short","length":53,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":147,"olType":false},{"type":"text","content":"LEXINGTON, Mass., March 19, 2025--(BUSINESS WIRE)--Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care.","length":345,"tagName":"p"},{"type":"text","content":"Colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system alike.1 The Colorectal Cancer in Focus survey, conducted online in the U.S. from October to December 2024, gathered insights from patients and healthcare providers (HCPs) to better understand their experiences and priorities in CRC treatment.","length":431,"tagName":"p"},{"type":"text","content":"Key Survey Insights:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Early-Onset CRC is on the Rise: More than half of HCPs reported an increase in CRC diagnoses among adults under 50, with 82% of surveyed patients diagnosed before that age.","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Gaps in the Standard of Care: Nearly all surveyed HCPs (93%) believe current treatment options for CRC are insufficient, with chemotherapy remaining the dominant approach despite its debilitating side effects.","length":209,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Rising Patient Demand for Chemotherapy Alternatives: A majority of patients highly value the possibility of treatments that do not involve chemotherapy. 61% expressed interest in new treatment options outside of chemotherapy, including immunotherapy (IO).","length":255,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Growing Interest in Immunotherapies: While awareness of IO therapies remains low among patients, 37% of HCPs c...